Sandbox:Polio prevention: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) No edit summary |
Tarek Nafee (talk | contribs) No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 21: | Line 21: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| IPV | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| IPV | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| *Serotype 1 <br> *Serotype 2 <br> *Serotype 3 | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| *Serotype 1 <br> *Serotype 2 <br> *Serotype 3 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| 1 dose | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| | ||
Line 28: | Line 27: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center"| ✔ | | style="padding: 5px 5px; background: #F5F5F5;" align="center"| ✔ | ||
|- | |- | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" colspan="7" | <SMALL><SMALL>†Countries at high risk for importation and subsequent spread</SMALL></SMALL><br> <SMALL><SMALL> ‡Countries at high risk for importation and subsequent spread</SMALL></SMALL> | ||
|- | |||
|} | |} |
Latest revision as of 16:14, 24 October 2016
Vaccine Type | Serotypes covered | Number of Doses | Vaccination Schedule in Endemic and High Risk Countries† | |||
---|---|---|---|---|---|---|
Birth | 6 weeks | 10 weeks | 14 weeks | |||
OPV | *Monovalent (Serotype 2) *Bivalent (Serotypes 1 & 3)‡ *Trivalent (Serotypes 1, 2, & 3) |
3 to 4 doses | ✔ | ✔ | ✔ | ✔ |
IPV | *Serotype 1 *Serotype 2 *Serotype 3 |
1 dose | ✔ | |||
†Countries at high risk for importation and subsequent spread ‡Countries at high risk for importation and subsequent spread |